In order to fully understand what biological changes are best predictive of the eventual cognitive decline associated with AD, it may be helpful in future analyses to include a wider selection of relevant biomarkers, such as volumetric Magnetic Resonance Imaging (MRI), tau PET, or fluid biomarkers. This evidence concerns the gene MAPT and Alzheimer disease.